The Eurofins Network Expands Its BioPharma Product Testing Offering in the United States With the Acquisition of Infinity Laboratories, Inc.
Summary
The acquisition further bolsters the Eurofins BioPharma and Medical Device Testing network’s national and global footprint to provide the most comprehensive and competitive service offering in the industry. In return, Infinity and its clients gain access to Eurofins extensive laboratory network, analytical portfolio and leading IT systems. network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. 62,000 staff across a decentralised and entrepreneurial network of more than 900 laboratories in over 1,000 companies in 62 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT).